Anthony Cheung
Oprichter bij ENGENE HOLDINGS INC.
Vermogen: 2 M $ op 30-04-2024
Actieve functies van Anthony Cheung
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ENGENE HOLDINGS INC. | Hoofd Techniek/Wetenschap/O&O | 24-04-2023 | - |
| Oprichter | 24-04-2023 | - | |
enGene, Inc.
 enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Directeur/Bestuurslid | - | - |
| Hoofd Techniek/Wetenschap/O&O | 16-07-2018 | - | |
| Oprichter | - | - | |
| Algemeen Directeur | 25-10-2011 | 16-07-2018 | |
| President | 25-10-2011 | 16-07-2018 | |
| Bedrijfssecretaris | 01-01-1999 | 25-05-2011 |
Loopbaan van Anthony Cheung
Opleiding van Anthony Cheung
| University of British Columbia | Undergraduate Degree |
| Tulane University School of Medicine | Doctorate Degree |
Statistieken
Internationaal
| Canada | 4 |
| Verenigde Staten | 2 |
Operationeel
| Chief Tech/Sci/R&D Officer | 2 |
| Founder | 2 |
| Director/Board Member | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ENGENE HOLDINGS INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Health Technology |
- Beurs
- Insiders
- Anthony Cheung
- Ervaring
